Evidence map›Paper›PMID 33459842›Full record

ArticleCancer immunology, immunotherapy : CII2021

Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.

Meghan J O'Melia, Margaret P Manspeaker, Susan N Thomas

Open access · greenAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. DCC-2036 induces repolarization of TAMs to M1 type and enhances CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Meghan J O'MeliaWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, IBB 2310, 315 Ferst Drive NW, Atlanta, GA, 30332, USA.
Margaret P ManspeakerParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Susan N ThomasWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, IBB 2310, 315 Ferst Drive NW, Atlanta, GA, 30332, USA. susan.thomas@gatech.edu.ORCID http://orcid.org/0000-0003-4651-232X
Georgia Institute of Technology · US

Funding

Research Training Program Plan on Cell and Tissue Engineering (CTEng)T32GM008433 · NIGMS · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J · 1991 to 2021
$7.1M
Mechanisms of impaired T-cell mechanosensing of melanoma antigensU01CA214354 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI KROGSGAARD, MICHELLE, ZHU, CHENG · 2017 to 2021
$3.9M
Melanoma immunotherapy targeting sentinel lymph nodesR01CA207619 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI THOMAS, SUSAN NAPIER · 2016 to 2020
$2.0M
IVIS Spectrum in vivo Imaging SystemS10OD016264 · OD · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J · 2015 to 2015
$595k
Foundation for the National Institutes of Health R01CA207619Foundation for the National Institutes of Health S10OD016264Foundation for the National Institutes of Health T32GM008433Foundation for the National Institutes of Health U01CA214354NCI NIH HHS R01 CA207619NCI NIH HHS U01 CA214354NIGMS NIH HHS T32 GM008433NIH HHS S10 OD016264Susan G. Komen CCR15330478
6 · The paper itself

Abstract

Triple negative breast cancer (TNBC) is a significant clinical problem to which immunotherapeutic strategies have been applied with limited success. Using the syngeneic E0771 TNBC mouse model, this work explores the potential for antitumor CD8

Indexed as

AnimalsAntigens, NeoplasmCD8-Positive T-LymphocytesCell Line, TumorCell SurvivalFemaleImmune Checkpoint InhibitorsImmunotherapyLymph NodesLymphoid TissueMiceMice, Inbred C57BLTriple Negative Breast NeoplasmsTumor MicroenvironmentAntigens, NeoplasmImmune Checkpoint InhibitorsDrug deliveryImmune checkpoint blockadeLymph nodesT cell primingTriple-negative breast cancerTumor dissemination

Identifiers

PMID33459842
PMCPMC8286278
OpenAlexW3121825884

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.